Mechano Growth Factor (MGF)
Mechano Growth Factor (MGF) is the C-terminal splice variant of IGF-1 (IGF-1Ec in humans) produced in response to mechanical loading, activating muscle satellite stem cells for local tissue repair with distinct signaling from systemic IGF-1.
Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor-1 produced locally in muscle and other tissues in response to mechanical loading, stretch, or damage. Designated IGF-1Ec in humans and IGF-1Eb in rodents, MGF differs from systemic IGF-1 through its unique C-terminal E peptide (24 amino acids), which confers distinct biological activity focused on satellite cell activation and the early proliferative phase of muscle repair.
Overview
MGF was identified by Geoffrey Goldspink's research group at University College London as a mechano-sensitive IGF-1 splice variant expressed rapidly following mechanical stress on muscle tissue. The IGF-1 gene produces multiple mRNA splice variants, with MGF (IGF-1Ec) distinguished by inclusion of a 49-base-pair insert in exon 5 that introduces a reading frame shift, generating a unique 24-amino-acid C-terminal E peptide. This E peptide is responsible for MGF's distinctive biological activity: preferential activation of muscle satellite (stem) cells during the early proliferative phase of repair, before they differentiate into mature myotubes. The extremely short plasma half-life (~5-7 minutes) limits unmodified MGF to local intramuscular use; PEGylation extends activity for systemic delivery.
Mechanism of Action
MGF signals through the IGF-1 receptor with potency comparable to full-length IGF-1, but its unique C-terminal E peptide confers additional biological activity not shared by other IGF-1 isoforms. The E peptide independently activates satellite cells -- the quiescent muscle stem cells residing between the sarcolemma and basal lamina -- driving them into the cell cycle and stimulating proliferation without premature differentiation. This is mediated through upregulation of Pax7 (satellite cell self-renewal marker) and MyoD (myogenic commitment factor) via PI3K/Akt and MAPK/ERK signaling cascades (Goldspink, 2005).
Critically, MGF acts in temporal sequence with mature IGF-1Ea: following mechanical stress, MGF is expressed first (within hours) to activate and expand the satellite cell pool, followed by IGF-1Ea expression (over days) to drive differentiation and protein synthesis. This temporal partitioning means MGF and mature IGF-1 represent distinct phases of the repair response rather than redundant signals (Hill & Goldspink, 2003).
Reconstitution Calculator
Mechano Growth Factor (MGF)
Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor-1
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Satellite Cell Activation
Goldspink and colleagues demonstrated that MGF is the primary signal for activating quiescent satellite cells following mechanical loading or muscle damage. In vitro studies show that the MGF E peptide alone (without the mature IGF-1 domain) is sufficient to stimulate satellite cell proliferation, indicating that the C-terminal peptide has independent signaling capacity. This is distinct from mature IGF-1, which more strongly drives terminal differentiation. The implication is that MGF specifically expands the satellite cell pool before committing cells to the myogenic lineage (Yang & Goldspink, 2002).
Mechano-Transduction and Exercise Response
MGF expression is rapidly upregulated in skeletal muscle following resistance exercise, stretch, or injury. Goldspink demonstrated a 25% increase in mean muscle fiber size when MGF was administered in conjunction with exercise protocols in mice. The mechano-sensitive expression of MGF represents a direct link between mechanical loading and the molecular signals that initiate muscle adaptation and repair. MGF expression declines with age, potentially contributing to the reduced regenerative capacity of aged muscle (Goldspink, 2005).
Cardiac Repair
MGF is expressed in cardiac tissue following myocardial infarction, where it activates cardiac stem cells and reduces cardiomyocyte apoptosis. Research from multiple groups demonstrates that MGF administration within hours of ischemic injury improves cardiac stem cell recruitment and reduces infarct size. The cardiac expression pattern mirrors skeletal muscle: rapid MGF upregulation followed by sustained IGF-1Ea expression during the remodeling phase (Hill & Goldspink, 2003).
Neuroprotection
MGF is naturally expressed in the brain following hypoxic injury and is over-expressed in regions of greatest neuron regeneration. Dluzniewska et al. demonstrated that MGF treatment improved muscle weakness and reduced motor neuron loss in mouse models of ALS. Elevated MGF levels in transgenic mice correlated with preserved cognitive function and reduced age-related neurodegeneration (Dluzniewska et al., 2005).
Age-Related Decline
MGF expression decreases significantly with aging, correlating with reduced satellite cell activation and impaired muscle regeneration in elderly individuals. Hill et al. showed that aged muscle produces less MGF in response to mechanical loading compared to young muscle, potentially explaining the blunted hypertrophic response to resistance training observed in older adults. Exogenous MGF administration may partially compensate for this age-related decline (Hill et al., 2003).
Safety Profile
MGF is a naturally occurring splice variant of IGF-1, providing a favorable theoretical safety basis. In animal studies, MGF and PEG-MGF have been administered without significant reported adverse effects at research doses. The extremely short half-life of unmodified MGF (~5-7 minutes) inherently limits systemic exposure and off-target effects. As an IGF-1 pathway activator, theoretical concerns include potential effects on pre-existing malignancies. No human clinical trials have established a comprehensive safety profile for MGF or its PEGylated form.
Clinical Research Protocols
MGF has not been evaluated in formal human clinical trials. Preclinical research protocols include:
- Muscle injury models: Cardiotoxin or barium chloride injection to induce controlled muscle damage in mice, followed by local MGF injection (10-100 mcg/kg). Satellite cell activation assessed via Pax7/MyoD immunostaining at 3-14 days post-injury
- Exercise protocols: MGF administered to mice following resistance loading, with muscle fiber cross-sectional area measured at 2-4 weeks (Goldspink, 2005)
- Cardiac ischemia: MGF delivered via biomaterial scaffolds to the infarct zone within 8 hours of coronary artery ligation in rats, with echocardiographic assessment at 4-8 weeks
Pharmacokinetic Profile
Mechano Growth Factor (MGF) — Pharmacokinetic Curve
Intramuscular injection (local), Subcutaneous (as PEG-MGF)Quick Start
- Route
- Intramuscular injection (local), Subcutaneous (as PEG-MGF)
Research Protocols
intramuscular Injection
The extremely short plasma half-life (~5-7 minutes) limits unmodified MGF to local intramuscular use; PEGylation extends activity for systemic delivery.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Or barium chloride injection to induce co | 10-100 mcg | Per protocol | — |
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Muscle injury models | 10-100 mcg | Per protocol | 3-14 days |
What to Expect
What to Expect
Rapid onset expected; half-life of ~5-7 minutes (unmodified) indicates fast-acting pharmacokinetics
Due to short half-life (~5-7 minutes (unmodified)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Human clinical trials conducted
- Naturally occurring compound
- Multiple peer-reviewed studies available
Caution
- Limited human data available
- Short half-life may require frequent dosing
Frequently Asked Questions
References (9)
- [7]
- [8]Yang & Goldspink -- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation FEBS Lett (2002)
- [10]
- [1]Hill & Goldspink *J Physiol* J Physiol (2003)
- [2]Yang & Goldspink *FEBS Lett* FEBS Lett (2002)
- [3]
- [4]
- [5]
- [6]Philippou et al *In Vivo* In Vivo (2009)
Mazdutide
Mazdutide (IBI362/LY3305677) is a GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. This oxyntomodulin-based peptide analog is administered once weekly by subcutaneous injection and is being evaluated in Phase 3 trials for obesity and type 2 diabetes, with the glucagon component providing additional energy expenditure and hepatic fat reduction benefits.
Melanotan I (Afamelanotide)
Melanotan I (afamelanotide) is a synthetic tridecapeptide analog of alpha-MSH with selective MC1R agonist activity, FDA-approved as Scenesse for erythropoietic protoporphyria (EPP). It stimulates eumelanin production for photoprotection without requiring UV exposure.